<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408954</url>
  </required_header>
  <id_info>
    <org_study_id>A3711045</org_study_id>
    <nct_id>NCT00408954</nct_id>
  </id_info>
  <brief_title>Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms</brief_title>
  <official_title>A Multi Center Randomized Cross Over Double Blind Third Party Open Placebo Controlled Pilot Study to Assess the Urodynamic Effects of Modified Release UK-369,003 in Men With Lower Urinary Tract Symptoms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in
      men with lower urinary tract symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>There is no specific primary endpoint for this study as it is not powered for that. It is mainly to generate hypotheses on the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum flow rate (Qmax)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystometric capacity</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void residual volume (PVR)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average flow rate (Qave)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume at first unstable contraction</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average detrusor pressure during micturition</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detrusor pressure at maximum flow rate (PdetQmax)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder outlet obstruction index (BOOI)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder contractility index (BCI)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder voiding efficiency (BE)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of unstable contractions</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean amplitude of unstable contractions</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Treatment Impact (PRTI)</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>UK-369,003</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UK-369,003</intervention_name>
    <description>100 mg MR tablet once daily for 2 weeks</description>
    <arm_group_label>UK-369,003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UK-369,003</intervention_name>
    <description>UK-369,003-100 mg MR formulation for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects, aged 40 years and above, with documented LUTS with an International
             Prostate Symptom Score (IPSS) ≥13.

          -  Clinical diagnosis of BPH

          -  Qmax 5 to 15 ml/sec with a voided volume of ≥150 ml

          -  Urodynamically defined bladder outlet obstruction

        Exclusion Criteria:

          -  prostate cancer

          -  Post-void residual urine volume &gt;200 ml

          -  Documented UTI

          -  History of relevant urological surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>612 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 11</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3711045&amp;StudyName=Urodynamic%20effects%20of%20UK-369%2C003%20in%20men%20with%20lower%20urinary%20tract%20symptoms.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <disposition_first_submitted>March 24, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 12, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 23, 2010</disposition_first_posted>
  <last_update_submitted>November 12, 2010</last_update_submitted>
  <last_update_submitted_qc>November 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

